Liquid Equity: The Extraction of Human Biological Capital

The multi-trillion-dollar pharmaceutical industry relies heavily on complex biologics and life-saving immunological therapies. Yet, the foundational raw material required to manufacture these extremely expensive treatments cannot be synthesized in a laboratory; it must be physically harvested from the veins of living humans. This absolute biological dependency has birthed a massive, highly unregul...